JP2005532045A5 - - Google Patents

Download PDF

Info

Publication number
JP2005532045A5
JP2005532045A5 JP2004501558A JP2004501558A JP2005532045A5 JP 2005532045 A5 JP2005532045 A5 JP 2005532045A5 JP 2004501558 A JP2004501558 A JP 2004501558A JP 2004501558 A JP2004501558 A JP 2004501558A JP 2005532045 A5 JP2005532045 A5 JP 2005532045A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
alone
factor
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004501558A
Other languages
English (en)
Japanese (ja)
Other versions
JP4460443B2 (ja
JP2005532045A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/013521 external-priority patent/WO2003093422A2/en
Publication of JP2005532045A publication Critical patent/JP2005532045A/ja
Publication of JP2005532045A5 publication Critical patent/JP2005532045A5/ja
Application granted granted Critical
Publication of JP4460443B2 publication Critical patent/JP4460443B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004501558A 2002-05-01 2003-04-30 抗凝固剤としての新規組織因子標的化された抗体 Expired - Fee Related JP4460443B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37656602P 2002-05-01 2002-05-01
PCT/US2003/013521 WO2003093422A2 (en) 2002-05-01 2003-04-30 Novel tissue factor targeted antibodies as anticoagulants

Publications (3)

Publication Number Publication Date
JP2005532045A JP2005532045A (ja) 2005-10-27
JP2005532045A5 true JP2005532045A5 (enExample) 2006-06-22
JP4460443B2 JP4460443B2 (ja) 2010-05-12

Family

ID=29401364

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004500787A Expired - Fee Related JP4567437B2 (ja) 2002-05-01 2003-04-30 抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質
JP2004501558A Expired - Fee Related JP4460443B2 (ja) 2002-05-01 2003-04-30 抗凝固剤としての新規組織因子標的化された抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004500787A Expired - Fee Related JP4567437B2 (ja) 2002-05-01 2003-04-30 抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質

Country Status (29)

Country Link
US (3) US7250168B2 (enExample)
EP (2) EP1503785B1 (enExample)
JP (2) JP4567437B2 (enExample)
KR (2) KR101013697B1 (enExample)
CN (2) CN100412090C (enExample)
AR (1) AR039515A1 (enExample)
AT (2) ATE427121T1 (enExample)
AU (2) AU2003225256B2 (enExample)
BR (2) BR0304659A (enExample)
CA (2) CA2483910A1 (enExample)
CR (1) CR7584A (enExample)
DE (2) DE60326970D1 (enExample)
DK (2) DK1503785T3 (enExample)
EC (2) ECSP045467A (enExample)
ES (2) ES2354419T3 (enExample)
HK (1) HK1080372A1 (enExample)
IL (3) IL164733A0 (enExample)
MX (2) MXPA04010795A (enExample)
NO (2) NO20035848L (enExample)
NZ (2) NZ536242A (enExample)
PE (1) PE20040597A1 (enExample)
PL (2) PL210582B1 (enExample)
PT (2) PT1549341E (enExample)
RS (2) RS102404A (enExample)
RU (2) RU2320366C2 (enExample)
TW (1) TWI343388B (enExample)
UA (2) UA85996C2 (enExample)
WO (2) WO2003093422A2 (enExample)
ZA (2) ZA200409694B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188830B1 (en) 1999-06-02 2010-01-20 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein ,nr10
EP1221482B1 (en) 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
EP2351855A1 (en) 2000-09-26 2011-08-03 Duke University RNA aptamers and methods for identifying the same
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
RS102404A (sr) * 2002-05-01 2006-12-15 Schering Aktiengesellschaft Nova antitela koja ciljaju tkivni faktor kao antikoagulanti
AU2003256299A1 (en) 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7833978B2 (en) * 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
CA2563176A1 (en) 2004-04-22 2005-11-10 Regado Biosciences, Inc. Improved modulators of coagulation factors
CN103665168A (zh) * 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
WO2008039206A2 (en) * 2005-10-05 2008-04-03 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
ATE485052T1 (de) * 2006-04-07 2010-11-15 Novo Nordisk Healthcare Ag Kovalenter faktor vii-gewebefaktor-komplex
AU2007255753B2 (en) 2006-06-08 2013-01-17 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
UA97961C2 (ru) * 2006-10-06 2012-04-10 Асахи Касеи Фарма Корпорейшн Способ лечения и/или улучшения диссеминированного внутрисосудистого свертывания крови
US9649499B2 (en) * 2007-03-28 2017-05-16 Medtronic ATS Medical, Inc. Method for inhibiting platelet interaction with biomaterial surfaces
AU2008300516A1 (en) * 2007-09-20 2009-03-26 Bracco Imaging Spa Method for the preparation of new oligoclonal antibodies
RU2596397C2 (ru) 2007-12-05 2016-09-10 Чугаи Сейяку Кабусики Кайся Терапевтическое средство от зуда
US8333973B2 (en) * 2008-01-02 2012-12-18 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP2321338A1 (en) * 2008-08-14 2011-05-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
US20110262466A1 (en) * 2008-10-16 2011-10-27 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2230251A1 (en) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antibodies specifically active in the coronary plaque and method for their identification
EP2470201A4 (en) * 2009-08-28 2013-01-30 Bayer Healthcare Llc COFACTORS ENABLING THE THROMBINIC ACTIVATION OF FACTOR VII AND THEIR USES
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
JP6143297B2 (ja) * 2010-06-04 2017-06-07 チウムバイオ・カンパニー・リミテッドＴｉｕｍＢｉｏ Ｃｏ．， Ｌｔｄ． 第ｖｉｉ因子活性を有する融合タンパク質
EP3281956A3 (en) 2010-06-15 2018-04-18 Genmab A/S Human antibody drug conjugates against tissue factor
CN103179982A (zh) * 2010-08-05 2013-06-26 科学与工业研究委员会 具有溶血栓和抗凝血性质的蛋白融合构建体
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
BR112017022101A2 (pt) 2015-04-14 2018-07-31 Chugai Seiyaku Kabushiki Kaisha composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo
FI3284480T3 (fi) 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2016176440A2 (en) * 2015-04-28 2016-11-03 Saint Louis University Thrombin-thrombomodulin fusion proteins as protein c activators
US11085031B2 (en) 2016-04-28 2021-08-10 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
TW201831508A (zh) * 2016-11-16 2018-09-01 美商拜耳保健有限責任公司 紅血球標靶因子ｖｉｉｉ及其使用方法
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CA3099547A1 (en) 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
WO2020070237A1 (en) * 2018-10-04 2020-04-09 Thrombosis And Coagulation Ab Method for the determination of protein s levels
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
IL293099B2 (en) 2019-11-20 2025-07-01 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
CN114686443B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用
CN114686444B (zh) * 2020-12-31 2024-05-31 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5589173A (en) * 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US4912207A (en) * 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
EP0458903A4 (en) * 1989-02-17 1992-06-17 Codon Soluble analogs of thrombomodulin
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5256770A (en) * 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
US5466668A (en) * 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
KR930008093B1 (ko) * 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
JPH0578397A (ja) * 1991-01-29 1993-03-30 Sumitomo Pharmaceut Co Ltd 血栓溶解タンパク質
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5916874A (en) * 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
AU752730B2 (en) * 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
JP2003527861A (ja) * 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
US6632791B1 (en) * 2000-06-21 2003-10-14 Schering Aktiengesellschaft Thrombomodulin analogs for pharmaceutical use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003057911A2 (en) 2002-01-08 2003-07-17 Bayer Healthcare Ag Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
RS102404A (sr) * 2002-05-01 2006-12-15 Schering Aktiengesellschaft Nova antitela koja ciljaju tkivni faktor kao antikoagulanti

Similar Documents

Publication Publication Date Title
JP2005532045A5 (enExample)
RU2004135306A (ru) Новые антитела к тканевому фактору в качестве антикоагулянтов
JP2005538046A5 (enExample)
Bochenek et al. Role of endothelial cells in acute and chronic thrombosis
Bíró et al. Studies on the interactions between C‐reactive protein and complement proteins
Hellwage et al. Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin
JP2004523205A5 (enExample)
Andersson et al. Binding of a model regulator of complement activation (RCA) to a biomaterial surface: surface-bound factor H inhibits complement activation
DK1446157T3 (da) Antistoffer til inhibering af blodkoagulation og fremgangsmåder til anvendelse deraf
Idell et al. Fibrin turnover in lung inflammation and neoplasia
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
Muzykantov et al. Immunotargeting of erythrocytes-bound streptokinase provides local lysis of a fibrin clot
RU2279890C2 (ru) Конъюгат, связывающий фибрин/фибриноген
Dyr et al. Molecular arrangement of adsorbed fibrinogen molecules characterized by specific monoclonal antibodies and a surface plasmon resonance sensor
Barbasz et al. The assembly and activation of kinin-forming systems on the surface of human U-937 macrophage-like cells
EP0668875A1 (en) Clot directed anticoagulant, process for making same and methods of use
EP1343823A2 (en) Antithrombotic von willebrand factor (vwf) collagen bridging blockers
Laich et al. Complement C4bC2 complex formation: an investigation by surface plasmon resonance
Develter et al. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody
CN105517565A (zh) 组织纤溶酶原激活物抗体及其用途
WO2001064876A3 (en) Human schizophrenia gene
JP7635223B2 (ja) 好中球細胞外トラップに関連する線維素溶解不全の診断方法
JP2003128577A (ja) 血管増殖性疾患の予防および治療のための血液凝固ｖｉｉ因子活性化プロテアーゼの使用
EP1534753A4 (en) ANTIBODY PEG POSITION SISOMERS, COMPOSITIONS CONTAINING THEM AND USE THEREOF
JPH07138296A (ja) Ｃｓｖｔｃｇ特異的腫瘍細胞の接着受容体の精製及び特性付け